Literature DB >> 2981278

Evidence of immunity induced by naturally acquired rotavirus and Norwalk virus infection on two remote Panamanian islands.

R W Ryder, N Singh, W C Reeves, A Z Kapikian, H B Greenberg, R B Sack.   

Abstract

For better understanding of the role of humoral immunity in ameliorating infections with rotavirus (RV) and Norwalk virus (NW), 305 Cuna Indians living on two isolated islands located off Panama's Carribean coast were surveyed daily for diarrhea over a seven-month period. Nine (8%) of 108 persons with a baseline RV antibody titer of greater than 1:4 developed RV infection compared with 70 (46%) of 151 persons with a baseline RV antibody titer of less than 1:4 (P less than .001). Thirty-eight (25%) of 151 persons of all ages with baseline RV antibody titer of less than 1:4 had at least one episode of RV diarrhea compared with 6 (6%) of 108 persons who had baseline RV antibody titers of greater than 1:4 (P less than .001). Thirty-two (47%) of 68 persons of all ages who had a baseline NW antibody titer of less than 1:100 developed NW infection compared with 30 (13%) of 237 persons with a baseline NW titer of greater than 1:100 (P less than .001). The high NW and RV infection rates and the excellent levels of protection provided by specific preexisting humoral antibody to these agents should promote activities aimed at developing vaccines for preventing these infections.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981278     DOI: 10.1093/infdis/151.1.99

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Dietary and prophylactic iron supplements : Helpful or harmful?

Authors:  S Kent; E D Weinberg; P Stuart-Macadam
Journal:  Hum Nat       Date:  1990-03

Review 2.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

Review 3.  Prospects and Challenges in the Development of a Norovirus Vaccine.

Authors:  Nicolas W Cortes-Penfield; Sasirekha Ramani; Mary K Estes; Robert L Atmar
Journal:  Clin Ther       Date:  2017-07-26       Impact factor: 3.393

4.  VP7 and VP4 genotyping of human group A rotavirus in Buenos Aires, Argentina.

Authors:  M H Argüelles; G A Villegas; A Castello; A Abrami; P D Ghiringhelli; L Semorile; G Glikmann
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

5.  Serological correlate of protection against norovirus-induced gastroenteritis.

Authors:  Amanda Reeck; Owen Kavanagh; Mary K Estes; Antone R Opekun; Mark A Gilger; David Y Graham; Robert L Atmar
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

6.  Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus.

Authors:  J J Gray; C Cunliffe; J Ball; D Y Graham; U Desselberger; M K Estes
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

Review 7.  Norovirus immunology: Of mice and mechanisms.

Authors:  Kira L Newman; Juan S Leon
Journal:  Eur J Immunol       Date:  2015-08-25       Impact factor: 5.532

8.  Subclass-specific serum antibody responses to recombinant Norwalk virus capsid antigen (rNV) in adults infected with Norwalk, Snow Mountain, or Hawaii virus.

Authors:  J J Treanor; X Jiang; H P Madore; M K Estes
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

9.  Persistent enteric murine norovirus infection is associated with functionally suboptimal virus-specific CD8 T cell responses.

Authors:  Vesselin T Tomov; Lisa C Osborne; Douglas V Dolfi; Gregory F Sonnenberg; Laurel A Monticelli; Kathleen Mansfield; Herbert W Virgin; David Artis; E John Wherry
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

Review 10.  Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.

Authors:  Negar Aliabadi; Ben A Lopman; Umesh D Parashar; Aron J Hall
Journal:  Expert Rev Vaccines       Date:  2015-07-29       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.